Adalimumab-adbm injection, a biosimilar to Humira ® (adalimumab), has been made available by Boehringer Ingelheim. Adalimumab-adbm injection is an interchangeable biosimilar and can be substituted for ...

Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin. Humira ...

Amjevita ™ (adalimumab-atto), a citrate-free biosimilar to Humira, was also made available in the US earlier this year. The product is supplied in a 40mg/0.8mL single-dose prefilled SureClick ...

Humira (adalimumab) is a prescription drug used for various conditions, including rheumatoid arthritis and plaque psoriasis. Mild side effects of the drug include injection site reactions, headache, ...

TOKYO, Sept 27, 2021 - (JCN Newswire) - - AbbVie GK, Eisai Co., Ltd., and EA Pharma Co., Ltd announced today the additional approval for a high- dose regimen in adult patients with ulcerative colitis ...

Humira is a brand-name subcutaneous injection prescribed for certain conditions, such as rheumatoid arthritis. Humira’s price, with and without insurance, can depend on several factors, such as ...

Another Humira biosimilar is here in Boehringer Ingelheim’s Cyltezo. Among the swarm of copycats, BI’s offering stands out because of its interchangeability tag, allowing it to be directly substituted ...

If you're one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...

Humira (adalimumab) is a long-term maintenance medication used to manage chronic conditions like Crohn’s disease and rheumatoid arthritis. For many people, this drug is not a short-term fix but a ...

Tennessee last year spent $48 million on a single drug, Humira — about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So ...

A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...